BCMA-CD19 cCAR T for the Treatment of Refractory Lupus

Summary

This is a Phase I, IIa, Single-Arm, interventional, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19-IL-15/IL15sushi cCAR T cells in patients with relapsed and/or refractory SLE, with or without Lupus Nephritis.

Timeline

Start

2026-01

Primary completion

2028-12

Completion

2028-12

Drugs

Indications